Baker Bros. Advisors LP Crispr Therapeutics Ag Transaction History
Baker Bros. Advisors LP
- $9.02 Billion
- Q4 2024
A detailed history of Baker Bros. Advisors LP transactions in Crispr Therapeutics Ag stock. As of the latest transaction made, Baker Bros. Advisors LP holds 1,308,011 shares of CRSP stock, worth $68.3 Million. This represents 0.57% of its overall portfolio holdings.
Number of Shares
1,308,011
Previous 843,075
55.15%
Holding current value
$68.3 Million
Previous $39.6 Million
29.96%
% of portfolio
0.57%
Previous 0.42%
Shares
3 transactions
Others Institutions Holding CRSP
# of Institutions
483Shares Held
64.1MCall Options Held
1.64MPut Options Held
1.93M-
Cathie Wood Ark Investment Management LLC | St. Petersburg, Fl8.97MShares$469 Million3.09% of portfolio
-
Capital International Investors Los Angeles, CA8.74MShares$457 Million0.07% of portfolio
-
T. Rowe Price Investment Management, Inc. Baltimore, MD3.81MShares$199 Million0.09% of portfolio
-
Black Rock Inc. New York, NY2.78MShares$145 Million0.0% of portfolio
-
Nikko Asset Management Americas, Inc.2.75MShares$143 Million1.21% of portfolio
About CRISPR Therapeutics AG
- Ticker CRSP
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 78,009,296
- Market Cap $4.07B
- Description
- CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious diseases using its proprietary Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform. Its CRISPR/Cas9 is a gene editing technology that allows for precise directed changes to genomic DNA....